Risk Factors for Treatment Failure and Recurrence after Metronidazole Treatment for Clostridium difficile-associated Diarrhea by �쟾�쁺�� et al.
original article
Gut and Liver, Vol. 4, No. 3, September 2010, pp. 332-337
Correspondence to: Jae Hee Cheon
Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine, 250 Seongsanno, 
Seodaemun-gu, Seoul 120-752, Korea 
Tel: +82-2-2228-1990, Fax: +82-2-393-6884, E-mail: geniushee@yuhs.ac
Received on December 21, 2009. Accepted on March 31, 2010.
DOI: 10.5009/gnl.2010.4.3.332
Risk Factors for Treatment Failure and Recurrence after 
Metronidazole Treatment for Clostridium difficile-associated Diarrhea
Kyu Sik Jung*, Jae Jun Park*, Young Eun Chon*, Eun Suk Jung*, Hyun Jung Lee*, Hui Won Jang*, 
Kyong Joo Lee*, Sang Hoon Lee*, Chang Mo Moon*, Jin Ha Lee*, Jae Kook Shin*, Soung Min Jeon*, 
Sung Pil Hong*,†, Tae Il Kim*,†, Won Ho Kim*,†,‡, and Jae Hee Cheon*,†,‡
*Department of Internal Medicine and †Institute of Gastroenterology, and ‡Brain Korea 21 Project for Medical Science, Yonsei University 
College of Medicine, Seoul, Korea
Background/Aims: The incidence of treatment failure 
or recurrence of Clostridium difficile-associated diar-
rhea (CDAD) following metronidazole treatment has in-
creased recently. We studied the treatment failure, re-
currence rate, and risk factors predictive of treatment 
failure and recurrence after metronidazole treatment 
for CDAD. Methods: We retrospectively identified 
consecutive patients who were admitted and treated 
for CDAD at a single tertiary institution in Korea over 
a recent 10-year period (i.e., 1998-2008). Results: 
Metronidazole was administered as the initial treat-
ment to 111 of 117 patients (94.9%) with CDAD. 
Fourteen patients (12.6%) had no clinical response to 
the metronidazole treatment, and in 13 patients 
(13.4%) CDAD recurred after successful metronidazole 
treatment. Diabetes mellitus (p=0.014) and sepsis 
(p=0.002) were independent risk factors for metronida-
zole treatment failure. Patients who had received sur-
gery within 1 month before CDAD developed were 
more likely to experience a recurrence after metroni-
dazole treatment (p=0.032). Vancomycin exhibited a 
higher response rate after treatment failure, and met-
ronidazole showed a reasonable response rate in the 
treatment of recurrence. Treatment failure and re-
currence rates increased with time after metronidazole 
treatment for CDAD over the 10-year study period. 
Conclusions: Our data suggest that diabetes mellitus 
and sepsis are independent risk factors for metronida-
zole treatment failure, and that operation history within 
1 month of development of CDAD is a predictor of a 
recurrence after metronidazole treatment. (Gut Liver 
2010;4:332-337)
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INTRODUCTION
  Clostidium difficile (C. difficile) is one of the most com-
mon causes of nosocomial infectious diarrhea, which ac-
counts for 15-20% of antibiotic-induced diarrhea.1,2 
Metronidazole has been the drug of choice in the treat-
ment of C. difficile-associated diarrhea (CDAD). Metroni-
dazole is less expensive, but it has been shown to be as 
effective as vancomycin. However, treatment failure or re-
currence with the metronidazole treatment has increas-
ed.3,4 Explanations for this include an increased use of 
broad-spectrum antibiotic and the emergence of more vir-
ulent and highly antibiotic-resistant strains of C. difficile.5 
However, there have been few studies concerning the data 
on the clinical risk factors predictive of treatment failure 
or recurrence after metronidazole treatment. Moreover, 
most investigations regarding CDAD exclusively came 
from Western countries. The effectiveness or the resist-
ance to antibiotics for CDAD varies by region or country.5 
Therefore, we evaluated the CDAD treatment failure rate 
and recurrence rate over the past 10 years at a single ter-
tiary hospital in South Korea (hereafter Korea) and exam-
ined the clinical risk factors associated with the treatment 
failure and recurrences.
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MATERIALS AND METHODS
  A retrospective review was performed to identify pa-
tients who had been admitted to Severance Hospital be-
tween March 1, 1998 and August 1, 2008 with a diag-
nosis of CDAD. Severance Hospital is a 2,000-bed tertiary 
hospital, affiliated with Yonsei University College of 
Medicine in Seoul, Korea. The diagnosis of CDAD was 
confirmed by a positive enzyme linked immunoassay for 
cytotoxin A (TOX A/B QUIK CHEK; Techlab, Blacksburg, 
VA, USA) in patients with diarrhea or documented pseu-
domembranous colitis (PMC) which was seen on a sig-
moidscopy or colonoscopy.6 PMC was defined as yel-
low-white plagues loosely adherent to the inflamed color-
ectal mucosa.6 No outpatients were included in this 
study. Patients were excluded from the study if: 1) they 
did not complete five days of initial antibiotic treatment 
for CDAD; 2) they had a coexistent gastrointestinal dis-
ease; or 3) clinical patient data was not completely 
recorded. In this study, treatment response was defined 
as the complete resolution of all symptoms (bowel move-
ment ＞3 times per day, fever ＞38oC, and abdominal 
pain) and no positive toxin assay after the treatment.7 
Treatment failure was defined as the persistence or the 
incomplete resolution of the symptoms, or positive toxin 
assay after 10 days of the treatment.3 Cytotoxin assay or 
culture was followed up only in the case of incomplete 
resolution of the symptoms. Recurrence was defined as 
the reappearance of either a symptom or a positive toxin 
assay within 90 days of the treatment response.4 Additio-
nal information about age, sex, combined comorbidity, 
place of residence, intensive care unit (ICU) admission, 
antibiotics used, symptom (fever, abdominal pain, bowel 
movement, and etc.), and laboratory findings (including 
WBC count, albumin level, liver function, and renal func-
tion) were obtained from the patients’ charts. The se-
verity of CDAD was assessed using the previously de-
scribed criteria.6 CDAD severity was defined to be severe 
if pseudomembranous colitis was found in endoscopic ex-
amination, or the patient was treated in the intensive care 
unit, or two or more of the following conditions took 
place: age ＞60 years, temperature ＞38.3oC, WBC ＞
15,000 cells/mm3, albumin level ＜2.5 mg/dL. For the 
metronidazole treatment, our clinic administered a dose 
of 1.5 g/day of oral metronidazole, and administered in-
travenous metronidazole to six patients because of their 
inability to be treated orally. For the vancomycin treat-
ment, a dose of 250 mg of oral vancomycin was ad-
ministered to all patients four times a day.
1. Statistical analysis
  Univariate comparison of the groups was performed us-
ing the independent Student’s t test for continuous varia-
bles and Fisher’s exact test for categorical variables. To 
estimate independent risk factors for the treatment failure 
and recurrence, the multiple logistic regression analysis 
was used. A p value of ＜0.05 was considered to be 
significant. Data are expressed as means±standard 
deviation. The statistical package used was SPSS version 
12.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
1. Patient characteristics and clinical courses
  We identified 208 patients who were diagnosed as 
CDAD by reviewing medical records. Among these pa-
tients, a total of 117 patients qualified for this study, 
while the other patients were excluded because of in-
sufficient information available from medical records 
(n=71), insufficient evidence of CDAD (n=12), or no 
treatment (n=8). The mean age of the patients was 62.5 
years±13.86 (range, 23-88). Fifty-four patients were male 
and 63 were female (ratio, 1:1.6). PMC developed in 58 
patients (49.6%), and 59 patients (50.4%) had positive 
toxin assay. Fifteen patients (12.8%) had both of PMC 
findings and positive toxin assay. Fourteen patients (12%) 
were diagnosed of sepsis and patients with sepsis were 
statistically more likely to maintain their previous anti-
biotics during CDAD (p=0.002). Durations of precipitat-
ing antibiotics use in sepsis were not different between 
metronidazole response (12.2±6.5 days) and failure group 
(13.0±5.5 days) (p=0.882). Types of antibiotics were not 
related to metronidazole failure in patients with sepsis 
(p=0.532). All patients (6 patients) with sepsis in metro-
nidazole failure group had severe CDAD, while 4 of 6 
(66.7%) in metronidazole response group had severe dis-
ease (p=0.078). Nine patients (7.7%) were treated in 
ICU. Twenty eight patients had diabetes mellitus, and the 
mean of glycated hemoglobin (HbA1c) was 6.3±1.7%.
  A flow chart of the clinical courses taken after CDAD 
treatment is shown in Fig. 1. Fourteen patients (12.6%) 
showed no positive reaction to the metronidazole treat-
ment, and 10 out of 11 patients (90.9%) responded to 
vancomycin after the initial metronidazole treatment 
failed. After a successful metronidazole treatment, re-
currence occurred in 13 out of 97 patients (13.4%). 
Among nine patients who were treated with metronida-
zole again, eight patients (88.9%) responded to the 
treatment. The other three patients were treated with 
vancomycin after the recurrence, and two patients re-
334   Gut and Liver, Vol. 4, No. 3, September 2010
Fig. 1. Of 117 patients with C. difficile-associated diarrhea (CDAD), 111 (94.9%) received an initial treatment of metronidazole. Of
these, 14 patients (12.6%) had no positive reaction. Of the responders, 13 (13.4%) experienced CDAD recurrence after successful
metronidazole treatment. After failure of metronidazole failed, 10 out of 11 patients (90.9%) subsequently responded to vancomycin.
In the cases of recurrence, eight out of nine patients (88.9%) responded to repeated metronidazole treatment.
Fig. 2. Metronidazole treatment failure rates over a recent 
3-year period (2006-2008) were 13.7% (7 of 51 patients), 
compared with 11.7% (7 of 60 patients) between 1998 and 
2005. Moreover, the recurrence rate after successful 
metronidazole treatment over the 3-year period from 2006 to 
2008 was 19.0% (8 of 42 patients), and the rate between 1998 
and 2005 was 9.1% (5 of 55 patients).
sponded (66%). The metronidazole treatment failure and 
recurrence after the treatment are compared according to 
years in Fig. 2. The rate of metronidazole treatment fail-
ure over the last three years (2006-2008) was 13.7 % (7 
of 51 patients) while the period between 1998-2005 re-
corded 11.7% (7 of 60 patients). Moreover, the re-
currence rate after successful metronidazole treatment 
over the last three years was 19.0% (8 of 42 patients), 
and that between 1998-2005 was 9.1% (5 of 55 patients).
2. Factors associated with metronidazole failure
  One of the major objectives in our study is to uncover 
risk factors for metronidazole treatment failure. Patients 
with diabetes mellitus and those with sepsis were less 
likely show a positive response to the metronidazole 
treatment for CDAD (p=0.015 and p＜0.01, respectively) 
(Table 1). Multivariate analysis still supports a positive 
correlation between diabetes mellitus/sepsis and treat-
ment failure (p=0.014 with an odd ratio of 3.905 [95% 
confidence interval, 1.234-12.358] and p=0.002 with an 
odd ratio of 8.906 [95% confidence interval, 2.474- 
32.066], respectively). Patients whose stool culture was 
positive for C. difficile were more likely to fail in the met-
ronidazole treatment (p=0.043) in univariate analysis, but 
this correlations was not significant in the regression 
analysis correlation (p=0.068) (Table 2). Age, gender, re-
nal failure, leukocytosis, albumin level ＜2.5 g/dL, stool 
toxin, finding of PMC on endoscopy, ICU admission, 
place of residence, use of immunosuppressive agent, use 
of histamine-2 receptor antagonists, use of proton pump 
inhibitor, kinds of antibiotic used for previous infection, 
duration of antibiotics, antibiotics maintenance during 
CDAD or any abdominal symptoms were not related to 
the failure of metronidazole treatment. In the analysis of 
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Table 1. Comparisons between the Response and Failure Groups Following Metronidazole Treatment
Variable Response group (n=97) Failure group (n=14) p-value
Age, mean (range) 63.05 (23-88) 60.14 (26-85) 0.150
Gender
  Female    54 (55.7)     6 (42.9) 0.379
  Male    43 (44.3)     8 (57.1)
Severe CDAD    65 (67.0)     8 (57.1) 0.224
Diabetes mellitus    21 (21.6)     7 (50.0) 0.015
Renal failure    28 (28.9)     5 (35.7) 0.506
Sepsis     8 (8.2)     6 (42.9) ＜0.001
Albumin level ＜2.5 (mg/dL)    11 (11.3)     3 (21.4) 0.245
ICU care     8 (8.2)     1 (7.1) 0.934
Immunosuppressive agent use    11 (11.3)     2 (14.3) 0.687
H2 antagonist    31 (32.0)     6 (42.9) 0.367
Antibiotics
  Cephalosporin    31 (32.0)     7 (50) 0.192
  Aminoglycoside     8 (8.2)     0 (0)
  Quinolone     9 (9.2)     0 (0)
  Other antibiotics*    14 (14.4)     0 (0)
  Use of more than 2 antibiotics    35 (36.1)     7 (50)
PMC on endoscopy    51 (52.6)     7 (50) 0.650
Stool culture positivity    58 (59.8)    12 (85.7) 0.043
Stool toxin positivity    50 (51.5)     9 (64.3) 0.190
Antibiotic maintenance†    33 (34.0)     7 (50.0) 0.184
Values are presented as mean (range) or number (%).
CDAD, C. Difficile-associated diarrhea; H2 antagonist, histamine-2 receptor antagonist; ICU, intensive care unit; PMC, pseudo-
membranous colitis.
*Other antibiotics indicate all kind of antibiotics except cephalosporin, aminoglycoside and quinolone; 
†
Antibiotic maintenance 
indicates receiving previous antibiotics during CDAD.
Table 2. Multivariate Analysis of Risk Factor for Failure of 
Metronidazole Treatment Failure 
Variables Odds ratio (95% CI) p-value
Diabetes mellitus 3.905 (1.234-12.358) 0.014
Sepsis 8.906 (2.474-32.066) 0.002
Stool culture positivity 6.107 (0.997-37.414) 0.068
CI, confidence interval.
Table 3. Comparisons between the Recurrence and Nonre-
currence Groups after Successful Metronidazole Treatment
Variable
Non-recurrence 
group
(n=84)
Recurrence 
group
(n=13)
p-value
Age ＞65   51 (60.7)    6 (46.2) 0.312
Gender
  Female   47 (56.0)   10 (76.9) 0.193
  Male   42 (50.6)    4 (30.8)
Severe CDAD   65 (77.4)    8 (61.5) 0.224
Renal failure   28 (27.5)    5 (33.3) 0.636
Surgery within 1 month    1 (1.2)    2 (15.4) 0.043
Sepsis    7 (8.3)    1 (7.7) 0.925
Alb ＜2.5 mg/dL   10 (11.9)    1 (7.7) 1.000
Stool toxin positivity   38 (45.2)    9 (69.2) 0.157
Hospital day, mean 42.7 (5-193) 47.5 (5-99) 0.632
 (range)
Antibiotic maintenance*   31 (36.9)    2 (15.4) 0.216
Values are presented as mean (range) or number (%).
CDAD, C. difficile-associated diarrhea.
*Indicate receiving previous antibiotics during CDAD.
patients with diabetes mellitus, HbA1c level was not sig-
nificantly different between metronidazole response group 
and metronidazole failure group (8.11±1.12 vs 7.45± 
1.84%). Moreover, well controlled diabetes mellitus 
(HbA1c＜7%) was not associated with metronidazole 
treatment response (p=0.615).
3. Factors associated with recurrence after metro-
nidazole treatment
  Patients who had surgery within a month before devel-
oping CDAD are more likely to recur after treatment, 
which was significant (p=0.043). An age greater than 65 
years, female gender, length of hospital stay, place of resi-
dence, renal failure, white blood cell count, maintenance 
of antibiotics, or any other clinical symptoms were not 
found to be related to a recurrence after the metronida-
zole treatment (Table 3). In multivariate analysis, a his-
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tory of surgery within a month before the treatment was 
found to be positively correlated with the recurrence of 
CDAD (p=0.032) with an odd ratio of 14.667 (95% con-
fidence interval, 1.234-174.273).
DISCUSSION
  C. difficile is associated with an uneven balance between 
normal colon bacterial flora and pathogenic bacteria. As a 
treatment of CDAD, metronidazole and vancomycin have 
been estimated to be more efficient than other anti-
biotics.8 A randomized trial comparing the efficacy of 
metronidazole and vancomycin for CDAD illustrated 
equivalent efficiency of the two antibiotics.9 The appear-
ance of vancomycin-resistant enterococci and a low cost 
have made metronidazole the drug of choice in CDAD 
treatment since the late 1980s. However, increasing rates 
of treatment failure and recurrence have been reported 
since the late 1990s. In two recent studies, treatment fail-
ure rates of metronidazole were reported to be 38% and 
78%, respectively.3,10 Pepin et al. reported the recurrence 
rate to be as high as 28.9% in their large-scale retro-
spective study. Moreover, another study reported the re-
currence rate as 28% after using metronidazole.7,10 There-
fore, our retrospective review focused on the results of 
metronidazole in the treatment of CDAD and the risk fac-
tors predictive of metronidazole treatment failure. This 
information is important because it enhances under-
standing in selecting patients who might benefit from 
vancomycin as an initial treatment of CDAD.
  In our study, most patients (94.9%) were initially treat-
ed with metronidazole. The response rate of metronida-
zole (87.4%) was high compared to the reports men-
tioned above. Based on our study, it is too early to gen-
eralize whether metronidazole is sufficient to be the first 
treatment option for CDAD. Our results were consistent 
with a recent study conducted in Korea. Byun et al.11 re-
ported that metronidazole seemed to be effective for 
CDAD treatment in a retrospective study on 86 Korean 
patients. However, we found a recently rising trend of 
metronidazole treatment failure. Complementary to our 
results, Pepin et al.10 reported increased treatment failures 
in the 2000s comparing to the 1990s. In North America, 
there were outbreaks of CDAD after the emergence of C. 
difficile ribotype 027/NAP-1 pulsotype in the early 2000s, 
and both the metronidazole treatment failure rate and the 
recurrence rate increased compared to the 1990s.10 
Currently, the reason of increasing tendency in the treat-
ment failure rate is not clear, but one possible ex-
planation is an increase in the emergence of strains re-
sistant to antibiotics. The recurrence of CDAD should be 
carefully monitored in the future, and a strain assay 
should be performed if treatment failure increases 
continuously.
  Next, we evaluated risk factors for the metronidazole 
treatment failure. In our study, risk factors with metroni-
dazole failure were the presence of diabetes mellitus and 
sepsis. Diabetic patients are more vulnerable to infection 
and more likely to have gastrointestinal motility pro-
blems.12 However, to our knowledge, there has been no 
evidence that the status of hyperglycemia is related to the 
metronidazole refractory CDAD, which indicates that this 
is a novel finding in our study. Future studies are needed 
to validate the relationship and pathophysiology between 
diabetes mellitus and drug resistant CDAD. 
  There are several possible explanations for the associa-
tion between sepsis and treatment failure. First, the ten-
dency of prolonged use of previous antibiotics during 
CDAD could be a possible reason. In our study, patients 
with sepsis were more likely to continue using the pre-
viously used antibiotics while treating CDAD. The main-
tenance of the previous antibiotics or prolonged use of 
antibiotics continues to delay normal flora from recover-
ing.4,13 However, duration of antibiotics use and specific 
types of antibiotics that were administered to patients 
with sepsis were not related with metronidazole treat-
ment failure in our study. Considering small number of 
patients in our study, the clarification of these relation-
ships need further investigations. Second, in most pa-
tients with sepsis in our study, CDAD severity was quite 
high (85.7%). Moreover, all patients with sepsis in met-
ronidazole failure group had severe CDAD in our study. 
In a previous study, severe CDAD was more likely to 
cause metronidazole treatment failure than moderate or 
mild CDAD.6 Although we found no direct relationship 
between CDAD severity and metronidazole failure in our 
study, severity of CDAD could be one explanation of our 
findings.
  After metronidazole treatment failure, vancomycin 
seemed to be efficient in most patients in our study. 
Patients who were treated with vancomycin after metroni-
dazole failure showed a significant reduction of C. difficile 
concentration.14 Vancomycin could be considered an effec-
tive treatment option when metronidazole fails to treat 
CDAD.
  Third, we tried to determine the risk factors for re-
currence after metronidazole treatment. In our study, only 
the surgical history a month before the treatment was 
found to be a related risk factor of recurrence after met-
ronidazole treatment. Gastrointestinal surgery has been 
reported as a risk factor for developing CDAD, but no 
specific kind of surgery was reported to be related with 
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recurrence.15 In our study, two patients underwent gastro-
intestinal tract surgery - one patient underwent colectomy 
for cancer, and another small bowel resection for perfo-
ration - and one orthopedic surgery (amputation of the 
diabetic foot). It is perhaps understood that surgery of 
the gastrointestinal tract or pelvis changes normal flora 
and may cause CDAD. However, the reason for its rela-
tion to the treatment recurrence is not necessarily 
certain.15 In our study, only a small number of patients 
had a history of surgery. Therefore, a larger confirmative 
study would be necessary to draw a solid conclusion con-
cerning this issue.
  After the documentation of treatment recurrence, 
69.2% of our patients were treated with metronidazole 
again, and the response rate was 88.9% and was consid-
ered efficient. However, vancomycin has a broad spectrum 
for gastrointestinal flora16 and tapering of vancomycin was 
efficient in treating recurred CDAD.17 Proper antibiotics 
for recurred CDAD should be chosen with careful consid-
eration of the clinical situation. In our study, only six pa-
tients were initially treated with vancomycin, and CDAD 
recurred in one patient. The recurrence rates between 
metronidazole and vancomycin treatments were similar in 
our study (12.6% vs 16.7%, respectively). Corresponding-
ly, in another study there was no difference in the re-
currence rate between the initial treatment of vancomycin 
and that of metronidazole.18 Considering our small num-
ber of vancomycin treatment group, further studies re-
garding the relationship between recurrence and the ini-
tial treatment of CDAD are needed.
  Our study has several limitations. This study can of 
course be affected by all the limitations of a retrospective 
design. The number of patients was relatively small and 
collected in a single institution. Finally, no strain of C. 
difficille was identified in this study.
  In conclusion, treatment failure and recurrence rates in-
crease after metronidazole treatment for CDAD, as in-
dicated in our study. Vancomycin showed a higher re-
sponse rate after treatment failure, and metronidazole still 
showed a reasonable response rate in the treatment of 
recurrence. Our data suggest that diabetes mellitus and 
sepsis are risk factors for the failure of metronidazole 
therapy of CDAD, and the history of surgery within a 
month before the treatment is a risk factor of recurrence.
REFERENCES
1. Barbut F, Corthier G, Charpak Y, et al. Prevalence and 
pathogenicity of Clostridium difficile in hospitalized 
patients. A French multicenter study. Arch Intern Med 
1996;156:1449-1454.
2. Bartlett JG. Clostridium difficile: history of its role as an 
enteric pathogen and the current state of knowledge about 
the organism. Clin Infect Dis 1994;18(Suppl 4):S265-S272.
3. Musher DM, Aslam S, Logan N, et al. Relatively poor out-
come after treatment of Clostridium difficile colitis with 
metronidazole. Clin Infect Dis 2005;40:1586-1590.
4. Nair S, Yadav D, Corpuz M, Pitchumoni CS. Clostridium 
difficile colitis: factors influencing treatment failure and re-
lapse--a prospective evaluation. Am J Gastroenterol 1998; 
93:1873-1876.
5. Kuijper EJ, Wilcox MH. Decreased effectiveness of metro-
nidazole for the treatment of Clostridium difficile in-
fection? Clin Infect Dis 2008;47:63-65.
6. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A com-
parison of vancomycin and metronidazole for the treatment 
of Clostridium difficile-associated diarrhea, stratified by 
disease severity. Clin Infect Dis 2007;45:302-307.
7. Fernandez A, Anand G, Friedenberg F. Factors associated 
with failure of metronidazole in Clostridium difficile-asso-
ciated disease. J Clin Gastroenterol 2004;38:414-418.
8. McFarland LV. Epidemiology, risk factors and treatments 
for antibiotic-associated diarrhea. Dig Dis 1998;16:292-307.
9. Teasley DG, Gerding DN, Olson MM, et al. Prospective 
randomised trial of metronidazole versus vancomycin for 
Clostridium-difficile-associated diarrhoea and colitis. Lancet 
1983;2:1043-1046.
10. Pepin J, Alary ME, Valiquette L, et al. Increasing risk of 
relapse after treatment of Clostridium difficile colitis in 
Quebec, Canada. Clin Infect Dis 2005;40:1591-1597.
11. Byun TJ, Han DS, Ahn SB, et al. Clinical characteristics 
and changing epidemiology of Clostridium difficile-asso-
ciated disease (CDAD). Korean J Gastroenterol 2009;54: 
13-19.
12. Joshi N, Caputo GM, Weitekamp MR, Karchmer AW. 
Infections in patients with diabetes mellitus. N Engl J Med 
1999;341:1906-1912.
13. Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. 
N Engl J Med 2002;346:334-9.
14. Al-Nassir WN, Sethi AK, Nerandzic MM, Bobulsky GS, 
Jump RL, Donskey CJ. Comparison of clinical and micro-
biological response to treatment of Clostridium difficile- 
associated disease with metronidazole and vancomycin. 
Clin Infect Dis 2009;47:56- 62.
15. Barbut F, Petit JC. Epidemiology of Clostridium diffi-
cile-associated infections. Clin Microbiol Infect 2001;7:405- 
410.
16. Edlund C, Barkholt L, Olsson-Liljequist B, Nord CE. Effect 
of vancomycin on intestinal flora of patients who pre-
viously received antimicrobial therapy. Clin Infect Dis 
1997;25:729-732.
17. McFarland LV, Elmer GW, Surawicz CM. Breaking the cy-
cle: treatment strategies for 163 cases of recurrent Clostri-
dium difficile disease. Am J Gastroenterol 2002;97:1769- 
1775.
18. Pépin J, Routhier S, Gagnon S, Brazeau I. Management 
and outcomes of a first recurrence of Clostridium diffi-
cile-associated disease in Quebec, Canada. Clin Infect Dis 
2006;42:758-764.
